TP53RK and plasma cell myeloma: For example, lenalidomide and pomalidomide can bind to and reduce TP53RK activity and thereby inhibit p53 phosphorylation and induce p53-mediated apoptosis in multiple myeloma cells in a CRBN-independent fashion43.